HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.
June 26, 2023 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics and maintained a $22 price target.
The reiteration of a Buy rating and maintenance of a $22 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Esperion Therapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100